Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 12, 2025British Journal of HaematologyOpen Access

Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

BLBenjamin J. LeeSGShawn P. GriffinJDJean Doh

Discussion

Loading...

Member takes

Overview

Retrospective study reveals CLIA-VEN treatment improves remission rates in AML without added toxicity.

Key Points

  • To compare the efficacy and toxicity of CLIA-VEN versus traditional 7 + 3 chemotherapy in AML.
  • Retrospective analysis of adult patients with newly diagnosed AML treated with CLIA-VEN or 7 + 3
  • Assessment of complete response rates, minimal residual disease, and toxicity
  • Utilization of propensity score weighting for demographic balancing
  • Higher cumulative incidence of composite CR with CLIA-VEN (90% vs. 54.8%; p = 0.002)
  • Increased MRD-negative CR with CLIA-VEN (93.8% vs. 40.9%; p < 0.001)
  • No significant increase in toxicity or early mortality with CLIA-VEN compared to 7 + 3

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69252e83c0ce034ddc355b96https://doi.org/10.1111/bjh.70253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025
  2. 2Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  3. 3Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  4. 4Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations
  5. 5Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026